

The background is a dark blue gradient. On the right side, there is a bright cyan light source with several thin, curved lines radiating outwards towards the left. On the left side, there are several thin, curved lines that appear to be part of a larger, faint graphic element.

MICROBA™

Investor Update

FY22 Annual Results

August 2022

Authorised for release by the Chairman and CEO

Disclaimer

This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**).

Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of this Presentation, being 20 July 2022. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs. This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.

Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Financial data – All dollar values in Australian dollars (A\$ or \$) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

Company Snapshot



Continuous YoY revenue growth over 5 years of operations



Partnerships with market leaders incl. **SYNLAB** (GR:SYAB), **Illumina** (NASDAQ: ILMN), **Genova Diagnostics**, and **G42**



Large, unique, proprietary microbiome databank



3 key therapeutic programs with lead IBD drug candidate **progressing to Phase 1 trial**




World-leading technology in the emerging **US\$4.89 billion** microbiome sector¹




Globally **leading microbiome expertise** complemented by drug discovery experts including Prof. Ian Frazer

FY22 Financial Highlights

(All figures in AU\$)





FY22

Testing Services - Key milestones

Testing Services - Key FY22 Milestones



USA OPERATIONS COMMENCED

Distribution partnership to open US Healthcare market commenced



GCC OPERATIONS COMMENCED

Distribution partnership to open Middle East market commenced



NEW PRODUCT LAUNCHED


Next generation healthcare product launched to health professionals



PARTNERSHIP SIGNED

Partnership signed to deliver a world-first personalised consumer health service

Driving US expansion and revenue growth



Growing pipeline

High quality new distribution partnership opportunities

>20

Active leads

9

Qualified opportunities

3

Progressing to draft terms

Prospect 1

- Reach into >30 countries
- Sells a leading GI testing product to healthcare practitioners across multiple major markets
- Strong scientific alignment between teams


Prospect 2

- >50k staff
- Reach into >50 countries
- >\$13B market cap
- Multi dimensional partnership opportunity

Expanding network of global distribution partners

Distribution agreements executed with global market leaders to distribute microbiome testing solutions powered by Microba’s world leading Analysis Platform technology.

						
 Metagenics	 SYNLAB V	 GENOVA DIAGNOSTICS	 G42 HEALTHCARE	 00000 midnight.health	 New partner	 New partner
AU & NZ • Metagenics is a leader in functional nutrition • Large allied health clinician customer base • In 2019, the Company finalised a distribution partnership for AU & NZ	Europe • Europe’s largest pathology company • Presence in over 40 countries • Manage 500m tests a year for 10m patients • Expansion across key countries in Europe are ongoing	US • Leading GI pathology company • >10,000 purchasing clinicians • In Dec 2021 the Company signed a distribution partnership for the US healthcare market • In June 2022 operations commenced	Middle East • Leading health-tech company • Harnessing data and advanced technologies for personalised care • In Feb 2022 the Company signed a distribution partnership for the GCC region • In June 2022 operations commenced	AU • Fast growth innovative consumer healthcare company backed by nib • In May 2022 the Company signed a partnership to deliver a world-first personalised consumer health service		
Launched Mid 2019	Launched Mid 2021	Launched Mid 2022	Launched Mid 2022	Planned Launch Q3 2022		



FY22

Therapeutics - Key milestones

Therapeutics - Key FY22 Milestones

Inflammatory Bowel Disease

PROGRESSING TO PHASE I



IBD program lead candidate MAP315 progressed in manufacturing, and CRO appointed preparing for Phase I clinical trial



Cancer Immunotherapy

LEADS DISCOVERED



Cancer program accelerated, ahead of schedule with therapeutic leads discovered and progressing towards pre-clinical animal studies



Autoimmune Diseases

COMMENCED




Autoimmune program with Ginkgo Bioworks commenced with delivery of first strains for analysis through the Ginkgo platform.




Inflammatory Bowel Disease program – MAP 315

Addressing a key gap in existing therapy for UC sufferers


Ulcerative Colitis Addressable Patient Population¹



Ulcerative Colitis Therapeutic Global Market Size²



MAP315 has the potential to provide **novel, potent therapeutic benefit** to UC patients through addressing a **key gap** in existing care – **epithelial and mucosal healing**



- More than 7 million patients worldwide live with IBD, and the incidence is increasing each year³
- Currently treated with anti-inflammatory and immunomodulatory medication to dampen the disease and control symptoms, with significant side effects
- Existing therapeutics fail to adequately address epithelial and mucosal healing with >50% of patients unable to achieve sustained remission¹, which frequently leads to surgical intervention⁴
- MAP 315 stimulates epithelial and mucosal healing⁵, a key unmet and novel treatment paradigm for patients living with this debilitating disease

¹ <https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf>

² <https://www.nature.com/articles/d41573-021-00194-5>, <https://www.alliedmarketresearch.com/ulcerative-colitis-market>


³ [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(19\)30333-4/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30333-4/fulltext)

⁴ <https://www.karger.com/Article/Fulltext/458006>

⁵ results from preclinical animal models, data on file

Inflammatory Bowel Disease program – MAP315

Rapidly progressing to Phase I



Development partners

IFF (NYSE: IFF) Allergy Treatment Partnership

Discovering novel microbiome treatments for allergies




- International Flavors & Fragrances Inc. (NYSE: IFF), \$29B¹ market cap
- Industry leader in food, beverage, health, biosciences
- Major global probiotics supplier

Microba has entered into an agreement with multinational player, IFF, to discover novel treatments for multiple forms of Allergy.

- Project to discover novel allergy treatments
- First milestone: multiple leads discovered for asthma and allergic rhinitis
- First step in a potential longer-term commercial relationship to develop novel allergy treatments.

Allergy Treatment Market²
Forecast to grow at CAGR of 6.8%



Outlook



Outlook

Global testing services growth

- Driving sales growth with recently commenced partnerships
- Expansion through onboarding new partnerships

Therapeutic advancement

- Advancing the company's key therapeutic programs
- Moving lead MAP315 asset into the clinic
- Progressing towards pivotal data and pharma transaction

Strong cash position


- \$30.5 million in cash or equivalents as at 30 June 2022
- Well funded to drive growth & therapeutic advancement

Appendix

Microba Overview

Microba's Commercial Model

Global testing services build a proprietary databank driving transformative novel therapies



**World-leading
microbiome analysis
technology** unlocks
routine testing and
microbiome therapies

up to **95%**
coverage¹

up to **34x**
more accurate²



THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA

Published in
 **frontiers**
in Microbiology

Other
Technology

Microba
Technology

MICROBA

¹ Calculated by analysing more than 10k samples across Microba's databank
² Microba achieves 6-34x lower false discovery rate than academic competitors
Parks, Donovan H., et al. "Evaluation of the Microba Community Profiler for Taxonomic Profiling of
Metagenomic Datasets From the Human Gut Microbiome." *Frontiers in microbiology* 12 (2021).

*Illustrative visualisation of the gastrointestinal tract and the additional
bacteria visible to Microba with its platform technology*

This graphic is for illustrative purposes only

The gut microbiome plays a key role in health & disease

**Modifying the
gut microbiome;
a key missing piece
to resolving
chronic disease**

6 in 10


People have a chronic
disease¹

>100

Clinical studies demonstrating
that **microbiome modulation**
can change chronic disease
outcomes²

What is the gut microbiome?

The community of microorganisms that inhabit
the lower digestive tract containing trillions of
microbial cells known as the gut microbiome.



Key disease mechanisms

Microbiome science is changing medicine and will **transform chronic disease management**



Microbiome therapy to treat chronic diseases

Microbiome modulating primary and adjuvant therapies are currently being developed to address autoimmune, inflammatory, metabolic, mental health disorders and cancer immunotherapy




Microbiome testing to match patients with the right treatment

Microbiome biomarkers and signatures are being developed for diagnosis, screening, drug response assessment and health risk monitoring.


Microba with its world leading technology operates in the **emerging US \$4.89 billion microbiome sector¹** which is transforming the large chronic disease management market²

Large, unique, proprietary databank

driving multiple therapeutic opportunities



Repeatable, scalable, data-driven platform **discovering novel monoclonal microbial cell therapies**




Proprietary microbiome databank driving **multiple therapeutic opportunities through a capital light platform**

Repeatable human first, data-driven therapeutic platform

Demonstrating rapid translation from data to first in human

Inflammatory
Bowel Disease
Program

CANDIDATE SELECTION PROCESS




New strategic partnership to deliver consumer health service



000o0 midnight.health

- Strategic partnership with nib-backed digital healthcare company Midnight Health
- Subscription model
- Personalised supplements delivered monthly based on microbiome test results – delivered with trained, registered pharmacists



Board of Directors



Pasquale Rombola
Chairman
Non-Executive Director

Mr Rombola has over 30 years of corporate and financial experience in Australia, Asia and the United Kingdom. He spent 19 years in senior positions with Morgan Stanley and Deutsche Bank, including 7 years in the role of Managing Director. Mr Rombola is a current Non-Executive Director of Audeara Limited, a leading hearing health company (ASX: AUA), he is the Chairman of Advantage Agriculture Pty Ltd a private agribusiness company. He was also formerly the Chairman and Director of Helix Resources Limited (HLX). Mr Rombola holds a Bachelor of Economics from the University of Western Australia.



Prof. Ian Frazer
Deputy Chairman and
Chair Medical Advisory Board

Professor Frazer is a clinician scientist, trained as a clinical immunologist. He is a Professor at the University of Queensland and is the current Chairman of the Australian Medical Research Advisory Board (AMRAB) which advises the Minister for Health on prioritising spending from the Medical Research Future Fund (MRFF). He is recognised as co-inventor of the technology enabling Gardasil - the leading vaccine currently used worldwide to help prevent cervical cancer.

Professor Frazer holds a Doctor of Medicine from the University of Melbourne and the following degrees from the University of Edinburgh: Bachelor of Medicine, Bachelor of Surgery and Bachelor of Science (Hons).



Dr Caroline Popper
Non-Executive
Director

Dr Popper is a US-based pathologist and business consultant with more than 20 years' experience in the international diagnostics, medical devices and drug discovery fields, including 10 years in senior management and marketing roles at the leading medical technology firm, Becton Dickinson & Company. Dr Popper has served in senior managerial and advisory positions at a variety of Fortune 500 and start-up companies, including bioMerieux and MDS Proteomics.

She holds a Bachelor of Medicine from the University of the Witwatersrand, Johannesburg; Master of Public Health – Health Policy and Health Economics from Johns Hopkins University, Baltimore.



Prof Gene Tyson
Co-Founder,
Non-Executive Director

Professor Tyson is a Professor of Microbial Genomics at The Queensland University of Technology and is the Director of the Centre for Microbiome Research.

Whilst at the University of California, Berkeley he was involved in publishing the first paper regarding the use of metagenomic sequencing for assessing microbial communities. Professor Tyson is also considered a world- leading expert in microbial analysis.

Professor Tyson holds a Bachelor Science (Hons) from the University of Queensland and a PhD from the University of California, Berkeley.



Dr Hyungtae Kim
Non-Executive Director

Dr Hyungtae Kim is an internationally experienced leader in the genomics field having held the positions of Chief Executive Officer of MacroGen Inc (MacroGen) from 2008 to 2014 and Chief Executive Officer, MacroGen Europe from 2015 to 2017.

Dr Kim is a Director of MacroGen Inc, a company listed on the KOSDAQ in South Korea.

Dr Kim is also a Director of the Gongwu Genome Information Foundation.

Dr Kim holds a PhD in molecular biology from George Washington University in Washington DC, USA.



Richard Bund
Non-Executive Director

Mr Bund is a Chartered Accountant and Director of Equipe Advisory Accounting firm. Mr Bund has more than 20 years experience in accounting and corporate finance and is the director of several private Australian companies.

Mr Bund is a Member of Chartered Accountants Australia and New Zealand. He holds a Bachelor of Commerce (Accounting) from the University of Adelaide and a Graduate Diploma in Chartered Accounting from Chartered Accountants Australia and New Zealand.

Medical Advisory Board



Prof. Ian Frazer

Deputy Chairman and Chair Medical Advisory Board, Clinical Immunologist

Professor Frazer is a clinician scientist, trained as a clinical immunologist. He is a Professor at the University of Queensland and is the current Chairman of the Australian Medical Research Advisory Board (AMRAB) which advises the Minister for Health on prioritising spending from the Medical Research Future Fund (MRFF). He is recognised as co-inventor of the technology enabling Gardasil - the leading vaccine currently used worldwide to help prevent cervical cancer.

Professor Frazer holds a Doctor of Medicine from the University of Melbourne and the following degrees from the University of Edinburgh: Bachelor of Medicine, Bachelor of Surgery and Bachelor of Science (Hons).



Dr Jakob Begun

Medical Advisory Board, Chair IBD Advisory Panel, Gastroenterologist

Dr Jakob Begun is a Practising Clinical Gastroenterologist and Senior Research Fellow in the Immunity, Infection, and Inflammation Program at Mater Research, The University of Queensland. He established an IBD centre at Queen Elizabeth II Hospital and an adolescent and young adult IBD centre at the Mater Hospital in Brisbane. Dr Begun is a senior lecturer at The University of Queensland School of Medicine and has a basic and translational laboratory at the Translational Research Institute. He maintains active collaborations with researchers at Harvard University and has formed new collaborations with researchers across Australia through his role as Chair of the Australia and New Zealand IBD Consortium.



Dr Paul Griffin

Medical Advisory Board, Infectious Disease Physician

Dr Paul Griffin is an Infectious Diseases Physician and microbiologist and was appointed as the Director of Infectious Diseases at Mater Health Services in 2013. In addition, Dr Griffin continues appointments as Principal Investigator at Q-Pharm, as Visiting Scientist/Honorary Research Fellow at Mater Medical Research Institute and Queensland Institute of Medical Research, and also as Senior Lecturer at The University of Queensland.

His research interests include clinical trials in the field of infectious diseases particularly malaria human challenge and transmission blocking studies, as well as the detection of antibiotic resistance particularly VRE by mass spectrometry in the clinical microbiology laboratory.



Dr Chris Hogan

Medical Advisory Board, General Practitioner

Professor Tyson is a Professor of Microbial Genomics at The Queensland University of Technology and is the Director of the Centre for Microbiome Research.

Whilst at the University of California, Berkeley he was involved in publishing the first paper regarding the use of metagenomic sequencing for assessing microbial communities. Professor Tyson is also considered a world- leading expert in microbial analysis.

Professor Tyson holds a Bachelor Science (Hons) from the University of Queensland and a PhD from the University of California, Berkeley.



Prof Maria Abreu

IBD Advisory Panel Member, Gastroenterologist

Crohn's and colitis physician-scientist. Director of Crohn's & Colitis Center, Professor of Medicine, Professor of Microbiology and Immunology, University of Miami, Miller School of Medicine, Florida, US.



Prof Jean-Frederic Colombel

IBD Advisory Panel Member, Gastroenterologist

Professor of Medicine at Icahn School of Medicine at Mount Sinai.

Former President of European Crohns & Colitis Organisation (ECCO).

Chair of the International Organisation of Inflammatory Bowel Disease (IOIBD).



Contact



Dr Luke Reid

Chief Executive Officer
luke.reid@microba.com



Pasquale Rombola

Chairman
pasquale.rombola@microba.com

Head Office

Level 10, 324 Queen Street
Brisbane QLD Australia

Laboratory

Princess Alexandra Hospital
Woolloongabba QLD Australia